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Introduction: Scintigraphy of renal system with radiopharmaceuticals extracts 
provides us with essential information as to assist the diagnosis and 
management of patients. In this research, effective doses of human’s organs 
due to gamma-rays of 99mTc-DTPA are estimated using the animal dissection 
data. 
Materials and Methods: In this study, the human absorbed and effective doses 
from 
99m
Tc-DTPA are obtained from animal organs data, using medical internal 
radiation dosimetry (MIRD) method and MCNP simulation code. In each stage, 
three mice were injected and sacrificed, and then their organs were dissected 
and counted by well detector.  
Results: The results of MIRD and MCNP simulation code indicated that the 
two mentioned methods are in agreement. Also, kidney (1.23E-03mGy/MBq), 
spleen (2.81E-03 mGy/MBq) and heart (2.75E-03 mGy/MBq) absorbed the 
most gamma dose compared to the other organs. 
Conclusion: According to the results and comparison with ICRP data, animal 
dissection model can be a useful tool for internal absorbed dose estimation of 
renal radiopharmaceuticals. 
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1. Introduction 
     The radiopharmaceuticals for studying 
the function and anatomy of renal can be 
categorized into three groups: first, the 
radiopharmaceuticals filtered by the 
glomerulus; second, the 
radiopharmaceuticals retained in the renal 
tubules via proximal tubule receptor-
mediated endocytosis from the glomerular 
filtrate [1-3]; and third, the 
radiopharmaceuticals primarily secreted by 











I-iodohippurane are excreted 
by the renal tubules [1,2]. They are helpful 
in evaluating patients with diminished renal 
function and kidney transplants. 
99m
Tc-
MAG3 is both filtered and excreted, and 
that is why some radiologists prefer it to 
other radiopharmaceuticals [1-3].  
99m
Tc-
DTPA is widely used in 
radiopharmaceutical kidney imaging but 
99m
Tc-MAG3 is used more than 
99m
Tc-
DTPA for patients with suspected 
obstruction and impaired renal function [1-
5]. 
99m
Tc-DMSA and Glucoheptonate are 
accumulated in the cortex; hence, they are 
helpful in evaluating renal scarring from 
chronic infection, infarction, renal mass,  
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I-iodohippurane is a renal agent used 
in diagnostics of kidneys’ malfunctions and 
renal tract obstructions. The renal excretion 
for this radiopharmaceutical is mainly 
through tubular secretion. However, 
131
I is 
not near the optimal conditions because of 
its physical properties and hence the image 
quality and radiation seems to be a burden, 
delivering a high radiation dose [7,8]. 
Erbslöh- Möller et al. indicated that 
131
I-




for the purpose of diagnosing renovascular 
hypertension (RVH) [8]. 
99m
Tc-DMSA as a 
static renal radiopharmaceutical is 
considered the reliable tool for 
investigating relative renal function and the 
most appropriate agent for renal cortical 
imaging. Radiopharmaceuticals can deliver 
radiation dose to organs because of the 
presence of their radioisotopes. Estimation 
of the absorbed dose from 
radiopharmaceuticals is an important part 
of the usage and development of novel 
agents. Many researches have been 
performed as for calculating the internally 
absorbed dose after radiopharmaceuticals’ 
administration [12-18]. In 2014, the 
Shanehsazzadeh et al. have recently 
obtained and compared effective dose of 
different organs of body resulting from 





In 2012, Shahbazi et al. determined the 
absorbed dose of different organs resulting 
from 
99m
Tc-dioxide phosphene where the 
highest dose of 38.73E-4mGy/MBq was 
delivered to the kidney [17]. Angela 
Keleher et al. (2004) calculated the dose of 
92.5MBq of 
99m
Tc - sulfur colloid on 
pregnant women, with the highest dose 
calculated to the fetus as 7.74E-2mGy [19]. 
There are different methods for estimating 
the internal radiation dose from diagnostic 
and therapeutic radiopharmaceuticals. One 
of the most important methods is “Medical 
Internal Radiation Dose (MIRD)”. This 
method is based on the absorbed fraction: it 
means that a fraction of emitted energy 
from source organs is absorbed on target 
organs [12]. Also, simulation with Monte 
Carlo method is another way. MCNP as a 
Monte Carlo code is used for calculating 
the absorbed dose. This is a general-
purpose code that can be used for some 
particles transport [20]. The aim of this 
study is the estimation of human absorbed 
dose of 
99m
Tc-DTPA resulting from 1 MBq 
after intravenous injection to mice, using 
MIRD and MCNP simulation code. 
 
2. Materials and Methods 
     This study is divided into two sections: 
theoretical and experimental. In the 
experimental section, for preparing the 
99m
Tc-DTPA, Technetium-99m was 
produced from the decay of 
99
Mo on an 







Tc in the form of sodium 
pertechnetate solution was eluted by sterile 
NaCl (0.9 %w/v) at room temperature. 
After radiolabeling of DTPA with 
99m
Tc, an 
activity of 3.7 MBq was injected via the tail 
vein. Mice experiments were completed in 
compliance with the regulations of our 
institution and with generally accepted 
guidelines governing such work. For this 
purpose, 3 time groups (each group 
consisting of 3 mice) is considered. 
After 10, 30 and 120 min, the mice in 
groups of three animals were sacrificed, 
organs of interest were dissected, weighed 
and radioactivity was measured in a gamma 
well-type detector. The percentage of the 
injected dose per gram (% ID/g) was 
calculated for each tissue.  Internally 
absorbed dose calculations were done based 
on the 0.14 MeV peak for 
99m
Tc. 
Absorbed dose on organs in overall is 
defined by following relation: 





                                            (1) 
d : Average energy of ionizing radiation 
for dm 
By considering the type of particle on 
creating biologic effects, equivalent dose is 
applied, which is equal to absorbed dose 
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multiplied by the radiation weighting 
factor. 
(2)H=DW                                                 
 
Table 1. Weighting factor of some radiations[12] 
The type of radiation Radiation weighting factor 
Alpha particles 20 
Beta particles 1 
Gamma & X Ray 1 
 
The effective dose is calculated by 
multiplying the equivalent dose (H) by a 
tissue weighting factor (WT). Effective dose 
is a quantity that considers the effect of 
taking beams by various tissues, in addition 
to considering the role of different beams 
on emergence of biologic effects, and 
equals to multiplying equivalent dose in 
tissue weighting factor [21,22]. 
(3)E=WT*H                                            
After preparation and injection of 
radiopharmaceuticals, animal studies were 
carried out in accordance with the UK 
Biological Council’s Guidelines on the Use 
of Living Animals in Scientific 
Investigations. The activity was measured 
with well-type counters before and after 
administration of the radiopharmaceutical. 
After injecting radiopharmaceutical to 
mice, they were sacrificed and their organs 
were dissected. Three samples from each 
organ were dissected, weighed and then 
counted to determine the percentage of 
injected dose per gram (which was 
equivalent to the percentage of injected 
activity per gram %IA/g: %ID/g); all the 
organ activity measurements were 
normalized to injected activity. 
Activity concentration of 
radiopharmaceuticals at times (t) was 
calculated as the percentage of injected 








/                        (4) 
where A tissue is the concentrated activity on 
sample tissue, M tissue is the mass of sample 
tissue and A injected is the total injected 
activity to mice. 
The dose of radiation delivered from a 
source tissue to a target tissue is dependent 
on the value of radioactivity in the source 
tissue and the time length of the 
radiopharmaceuticals resides in the source 
tissue. Due to the continuous uptake and 
elimination of the radiopharmaceutical 
administered to the living system and 
physical decay of the radionuclide, the 
radioactivity in each organ is dependent on 
time (function of time). The cumulated 
radioactivity, A
~
 , can be shown as eq. (5): 







htissueh dttAA                           (5) 
Ah (t): activity of each tissue on time (t).  A ᷉ 
accounts for the radioactivity in the tissue, 
and how long it resided in source tissue. 
After calculating the activity for organs at 
different times, related activity curves were 
drawn for each. Then, using the curve-
fitting method, cumulated radioactivity 
values were obtained. 
For converting accumulated activity of 
mice organs to human organs, Sparks and 
Idogan method is used which is shown in 
eq. (6) [9,18]: 










  (6) 
Due to the length and attenuation between 
the source tissues and target tissues, a mere 
fraction of the energy emitted by the source 
tissue is absorbed by the target organ. This 
energy fraction needs to be quantified so 
that the total absorbed dose by the target 
tissue can be estimated. 
The equation for absorbed dose in the 
MIRD system is shown as eq. (7): 
           
m





                      (7) 
where ni is the number of radiations with 
energy E emitted per nuclear transition,  Ei 
is the energy per radiation (MeV),  i  is the 
fraction of energy absorbed in the target, m 
is the mass of target region (g or kg) and k 
is proportionality constant 
(rad-g/ -hr-MeV or 
Gy-kg/MBq-sec-MeV). 
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Absorbed dose was calculated by using 
MIRD formula [18]: 
 SA = D
~
                          (8( 




)(        (9) 
where D(rk) is the absorbed dose of the 
target tissue (rad or Gy),  is the 
accumulated activity in source tissue -
hr or MBq-sec) and )( hk rrS  ,
 called S 
factor, which is defined as the mean 
absorbed dose to the target region rk per 
unit of accumulated activity in the source 
region rh. The S factor represents the 
physical decay characteristics of the 
radioisotopes, the range of the emitted 
radiations, and the organ size. The S factors 
have been taken from the tables presented 
in the medical internal radiation dose No. 
11 [15] and also available in 
http://doseinfo-
radar.com/RADARphan.html.  
By calculating the accumulated activity 
from eq.5 for mice and then converting it to 
human accumulate activity from eq.6, the 
absorbed dose taken from different organs 
can be calculated by eq.8. The calculated 
dose for each organ is obtained through the 
sum of absorbed doses from radiation, 
emitted from other organs in addition to the 
absorbed dose.  
In continuation, The absorbed dose of 
different body organs were obtained by 
converting the mice results to the human 
and accumulating the activity through both 
methods. On the first stage, equivalent 
absorbed dose and effective absorbed dose 
of different organs after injection of 
radiopharmaceutical were obtained by 
using MIRD and S factor, which is shown 
as Tables 2 and 3.  
For dose estimation by MCNP simulation 
code, the absorbed and effective doses of 
some organs such as lungs, liver, spleen, 
heart, stomach, pancreas, adrenal, intestine 
and kidneys are estimated within an adult 
male ORNL phantom (input file of ORNL 
phantom - adult male (Eckerman et al., 
1996)). To that end, a grown male phantom 
consisting of soft tissue materials, bone 
tissue and lung tissue is applied. Tissues 
with accumulated activity are applied as the 
radioactive volume sources. MCNP as a 
Monte Carlo code needs the source for a 
problem to be specified in a user defined 
input file. In the source card, particle type, 
source position and distribution, energy, 
and direction of starting particles were 
specified. For simulation of our work, it is 
assumed that the radiopharmaceuticals 
were uniformly distributed throughout the 
organs. The radiopharmaceuticals used in 
this research emit gamma (
99m
Tc) radiation.  
Then, human phantom was stimulated on 
MCNP code; the amount of effective 
absorbed dose of different organs for these 
radiopharmaceuticals is shown on Tables 2 
and 3. To reduce the statistical error (below 
5%), 1E7 particles were determined for 
NPS. The source energy was chosen based 
on the 0.14 MeV peak for 
99m
Tc. 
Tallies of F6 and *F8 can be applied for 
calculation of absorbed dose in MCNP 
code. In this simulation, both *F8 and F6 
was used to calculate absorbed dose in the 
mentioned tissues (F6 tally only for gamma 
source was used). 
 
3. Results 
     Figures 1-6 show the percentage of 
injected dose per gram at times of 10, 30 
and 120 minutes after intravenous injection 
of 
99m
Tc-DTPA on different organs of 
mice.
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F(t)= 31.9 exp(-2.473 t)
Exponential function of percent injected dose









Figure 1. The clearance curves of kidneys after IV injection of 99mTc-DTPA The horizontal axis is displayed as hours 
post injections (Mean values as the percentage of administered activity per gram (%ID/g)) 







F(t)= 2.268 exp(-1.529 t)
Exponential function of percent injected dose









Figure 2. The clearance curves of liver after iv injection of  99mTc-DTPA. The horizontal axis is displayed as hours post 
injections (Mean values as the percentage of administered activity per gram (%ID/g)) 
 




















Exponential function of percent injected dose









Figure 3. The clearance curves of heart after iv injection of  99mTc-DTPA. The horizontal axis is displayed as hours post 
injections (Mean values as the percentage of administered activity per gram (%ID/g) 
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F(t)=10.43 exp (-1.005 t)
Exponential function of percent injected dose









Figure 4. The clearance curves of spleen after iv injection of 99mTc-DTPA. The horizontal axis is displayed as hours 
post injections (Mean values as the percentage of administered activity per gram (%ID/g)) 
 










F(t)= 8.029 exp(-1.067 t)
Exponential function of percent injected dose









Figure 5. The clearance curves of lung after iv injection of 99mTc-DTPA. The horizontal axis is displayed as hours post 
injections (Mean values as the percentage of administered activity per gram (%ID/g)) 
 






F(t)= 3.75 exp(-2.013 t)
Exponential function of percent injected dose









Figure 6. The clearance curves of intestine after iv injection of 99mTc-DTPA. The horizontal axis is displayed as hours 
post injections (Mean values as the percentage of administered activity per gram (%ID/g)) 
 
After calculating the absorbed dose by 
MIRD and MCNP methods, the amount of 
effective absorbed dose of different organs 
for this renal radiopharmaceutical was 
obtained. The results of both methods are 
indicated in Tables 2 and 3.
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Table 2.  Assessment of human effective dose based on mouse data after intravenous administration of 99mTc- DTPA 











Human Absorbed Dose 
mGy/MBq (Stabin et al.[8]) 
Liver 4.79E-04 0.04 1.92E-05 1.80E-03 
Intestine 3.54E-04 0.12 4.25E-05 8.50E-03 
Pancreas 1.03E-03 0.01 1.03E-05 2.10E-03 
Kidneys 1.23E-03 0.01 1.23E-05 5.70E-03 
Spleen 2.81E-03 0.01 2.81E-05 1.90E-03 
Heart 2.75E-03 0.01 2.75E-05 1.70E-03 
Lungs 1.15E-03 0.12 1.38E-04 1.50E-03 
Stomach 1. 2E-03 0.12 1.44E-04 1.90E-03 
Adrenals 6.98E-04 0.01 6.98E-06 2.00E-03 
a  
 If injected 1MBq activity of radio-tracer. 













Human Absorbed Dose 
mGy/MBq (Stabin et al.[8]) 
Liver 2.65E-04 0.04 1.06E-05 1.80E-03 
Intestine 3.49E-04 0.12 4.19E-05 8.50E-03 
Pancreas 1.15E-03 0.01 1.15E-05 2.10E-03 
Kidneys 1.34E-03 0.01 1.34E-05 5.70E-03 
Spleen 3.46E-03 0.01 3.46E-05 1.90E-03 
Heart 2.08E-03 0.01 2.08E-05 1.70E-03 
Lungs 3.12E-03 0.12 3.74E-04 1.50E-03 
Stomach 1.56E-03 0.12 1.88E-04 1.90E-03 
Adrenals 6.62E-04 0.01 6.62E-06 2.00E-03 
a  
 If injected 1MBq activity of radio-tracer. 
 
4. Discussion 
     Labeling of 
diethylenetriaminepentaacetic acid (DTPA) 
with Tc-99m, sodium pertechnetate results 
in the preparation of radiopharmaceutical 
99mTc-DTPA. The individual renal mode 
of clearance for this radiopharmaceutical 
promotes its usage in scintigraphy study of 
kidneys. The IV administered 99mTc-
DTPA (with a half-life of 70 minutes) is 
filtered by the renal glomeruli, thereby 
allowing assessment of glomerular filtration 
rate (GFR). So, it is the most suitable 
substance for measuring glomerular 
filtration (GFR) and good imaging of renal 
parenchyma. 
The use of a radiopharmaceutical requires 
calculation of its biodistribution in some 
models prior to its clinical applications [25-
29]. In this study, internal radiation 
dosimetry of the well-known renal imaging 
agent, 99mTc-DTPA, was calculated and 
compared (based on mouse data) through 
two important methods. Based on the 
assumption that the biodistribution of 
radiopharmaceuticals could be similar in 
mouse and in human (ICRP 103), 
assessment of absorbed dose in human body 
from small animal such as mouse may be 
useful for accelerating the planning of new 
radioactive compounds to be used in 
clinical experiments (recommendations of 
ICRP 62). There are various methods to 
estimate the absorbed dose after 
radiopharmaceuticals injection, such as 
Monte Carlo Codes, MIRD, etc.  
The results of 
99m
Tc-DTPA distribution in 
body using the two mentioned methods 
showed that the absorbed dose in kidney 
(1.23E-03mGy/MBq), spleen (2.81E-03 
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mGy/MBq) and heart (2.75E-03 mGy/MBq) 
are considerable. This may be related to the 
chemical structure and stability of 
radiopharmaceuticals.  
The results of MIRD and MCNP code show 
a decent agreement for 99mTc-DTPA, and 
the difference between absorbed doses in 
more organs was lower than 10 percent. 
The mouse model dosimetry was not in 
good agreement with Stabin’s dosimetry 
data. It can be due to different uncertainties 
in both methods, different measurement 
instruments, excluding the rest of the rays 
(only gamma energy=0.14 MeV is used), 
mouse to human conversion factor (Sparks 
and Idogan equation), difference between 
human and mouse tissues geometry, etc. 
According to the mean effective half-life of 
radiopharmaceutical which is reported to be 
short in body, it was obvious that all the 
injected activity should be cleared from the 
main organs in short time and it would be 
better to have more time points before one-
hour to get better results for calculating the 
cumulative activity; consequently, the 
selection of low time points because of 
some limitations might be one of the 
reasons of difference between mouse and 
Stabin’s model results. 
In general, there is a good agreement 
between MCNP and MIRD results for the 
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